SLC5A2 and type 2 diabetes mellitus: In conclusion, our meta-analysis demonstrated that SGLT2 inhibitors had beneficial effects on the kidney by lowering the risk of albuminuria development or progression and reducing the risk of ESRD compared with placebo or other antidiabetic drugs in patients with type 2 diabetes.